The Vaccine and Infectious Disease Division is committed to eliminating death and disease attributed to infections. To that end, investigators in the Immunology and Vaccine Development Program (IVD) focus on translating fundamental knowledge about the immune system and its regulation to the design of vaccines. We aim to create effective vaccines that elicit maximum protection against cancer and infectious diseases, including COVID-19, HIV, tuberculosis, malaria and Ebola.
The scientists in our program concentrate on basic research in the laboratory. To test and evaluate novel vaccine candidates and therapeutics, we collaborate extensively with the biostatisticians and clinicians in VIDD and throughout Fred Hutch as well as with international colleagues in major global networks.
IVD researchers are experts in the molecular underpinnings of the host immune response as well as in host genetics. We also concentrate on designing vaccines and preventative therapeutics that raise robust immunity in people at risk of cancer and other deadly infectious diseases.
Dr. Julie McElrath, a world-renowned scientist, is at the forefront of an unprecedented, global effort to understand how COVID-19 affects the immune system, as well as test safe and effective vaccines against the virus.
Fred Hutch leads the HIV Vaccine Trials Network, a critical global effort aimed at creating an effective vaccine against HIV. HVTN operates over 30 sites on five continents and has collaborations with researchers at numerous internationally renowned research institutes.
IVD faculty member Dr. James Kublin leads clinical trials testing the capacity of genetically modified malaria parasites or other vaccine candidates to raise effective immune responses in humans while not causing disease.
The tools and techniques we have developed and discoveries we have made have broad applicability to many challenging infectious diseases with significant global health impacts. Researchers within our program study a variety of diseases, with new findings in one often translating to exciting new avenues of research in another.
Fred Hutch directs major worldwide, multicenter clinical studies aiming to develop vaccines against HIV and other global infectious diseases. We also house the central operations and laboratory functions of a prestigious nationwide network for cancer immunotherapy clinical trials. Researchers from IVD play leadership roles in these initiatives.
In 2013, Fred Hutch established the Hutchinson Centre Research Institute – South Africa, a nonprofit, South African entity that includes the Cape Town HIV Vaccine Trials Network (HVTN) Immunology Laboratory. A state-of-the-art laboratory and training facility, the Cape Town lab supports clinical trials conducted by the HVTN.
IVD faculty member Dr. James Kublin serves as medical director of The Seattle Malaria Clinical Trials (Seattle MCTC). A translational research center established by Fred Hutch and the Center for Infectious Disease Research (CIDR), Seattle MCTC tests experimental malaria vaccines and drugs in human clinical trials.
The mission of HIV/AIDS Network Coordination (HANC) is to support the science and operations of six critical HIV/AIDS clinical trials networks funded by the National Institutes of Health. IVD faculty member Dr. Jeffrey Schouten directs HANC, providing leadership and institutional logistical support for cross-network coordination since 2004.